ECOG-ACRIN BY THE NUMBERS

Loading Quotes...

News and Announcements

Registration is open for the Spring 2018 Group Meeting

Follow this link

We’ve moved! On January 29, 2018, our headquarters at 1818 Market Street, Philadelphia, moved to Suite 3000 (from Suite 1100)

We are now accepting proposals for ctDNA analysis of blood specimens collected from patients in the NCI-MATCH / EAY131 trial

Follow this link

Listen to a recorded webinar on patient-reported outcomes research by David Cella, PhD

Follow this link

Watch this video that explains the E2112 research study, for men and women with advanced breast cancer

Follow this link to view this CIRB-approved resource

We are now accepting nominations for the 2018 Young Investigator Award, until March 30th

Follow this link for eligibility requirements and nomination instructions

Fellows! Apply for the Paul Carbone, MD Fellowship Award by March 23rd

Follow this link for eligibility requirements and application instructions

Mark your calendar for Group meetings through 2021

Follow this link

TMIST breast cancer screening trial featured by Kaiser Health News

Follow this link

 

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

Robert L. Comis, MD
Group Co-Chair


Mitchell D. Schnall, MD, PhD
Group Co-Chair

 

 

 

 

 

 

img img
img
img